{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vascular&page=16",
    "query": {
      "condition": "Vascular",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 15039,
    "total_pages": 1504,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vascular&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vascular&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T05:22:05.592Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07162363",
      "title": "Synergistic Minimally Invasive Surgery and Deferoxamine in ICH",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Intracerebral Hemorrhage",
        "ICH - Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Minimally Invasive surgery (MIS)",
          "type": "PROCEDURE"
        },
        {
          "name": "Deferoxamine",
          "type": "DRUG"
        },
        {
          "name": "Standard Medical Care (SMD)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Illinois Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 240,
      "start_date": "2026-03-01",
      "completion_date": "2028-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07162363"
    },
    {
      "nct_id": "NCT04401293",
      "title": "Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sars-CoV2",
        "COVID"
      ],
      "interventions": [
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Prophylactic/Intermediate Dose Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 257,
      "start_date": "2020-04-26",
      "completion_date": "2021-05-14",
      "has_results": true,
      "last_update_posted_date": "2021-11-22",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 6,
      "location_summary": "Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Bay Shore",
          "state": "New York"
        },
        {
          "city": "Huntington",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Queens",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04401293"
    },
    {
      "nct_id": "NCT00208104",
      "title": "Motivational Interviewing",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Essential Hypertension"
      ],
      "interventions": [
        {
          "name": "Motivational Interviewing",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2002-07",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2013-02-18",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00208104"
    },
    {
      "nct_id": "NCT07911033",
      "title": "Relationship Between Insulin Dose and Complications in Type 1 Diabetes",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 1 Diabetes",
        "Cardiovascular Diseases (CVD)",
        "Severe Albuminuria",
        "Estimated Glomerular Filtration Rate (eGFR)",
        "Hypoglycemia (Diabetic)",
        "Vascular Calcification",
        "Carotid-femoral Pulse Wave Velocity",
        "Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Routine/prescribed exogenous insulin dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rachel Miller",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "2027-01",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07911033"
    },
    {
      "nct_id": "NCT03728985",
      "title": "Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Thoracoabdominal Aortic Aneurysm"
      ],
      "interventions": [
        {
          "name": "GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "W.L.Gore & Associates",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2019-06-17",
      "completion_date": "2030-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03728985"
    },
    {
      "nct_id": "NCT01484015",
      "title": "Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Lymphoblastic Leukemia",
        "Adult Acute Myeloid Leukemia",
        "Adult Burkitt Lymphoma",
        "Adult Diffuse Large Cell Lymphoma",
        "Adult Diffuse Mixed Cell Lymphoma",
        "Adult Diffuse Small Cleaved Cell Lymphoma",
        "Adult Hodgkin Lymphoma",
        "Adult Immunoblastic Large Cell Lymphoma",
        "Adult Lymphoblastic Lymphoma",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Breast Cancer",
        "Chronic Eosinophilic Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Neutrophilic Leukemia",
        "Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Disseminated Neuroblastoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Grade 1 Follicular Lymphoma",
        "Grade 2 Follicular Lymphoma",
        "Grade 3 Follicular Lymphoma",
        "Malignant Testicular Germ Cell Tumor",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Multiple Myeloma",
        "Mycosis Fungoides/Sezary Syndrome",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neutropenia",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Ovarian Epithelial Cancer",
        "Ovarian Germ Cell Tumor",
        "Plasma Cell Neoplasm",
        "Poor Prognosis Metastatic Gestational Trophoblastic Tumor",
        "Primary Myelofibrosis",
        "Prolymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Splenic Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "cefepime hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2011-02",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01484015"
    },
    {
      "nct_id": "NCT07601425",
      "title": "Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)",
        "Osler Weber Rendu Disease"
      ],
      "interventions": [
        {
          "name": "ATV-1601",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atavistik Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-07-27",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • San Diego, California • Augusta, Georgia + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07601425"
    },
    {
      "nct_id": "NCT00432458",
      "title": "Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2003-07",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2012-07-04",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00432458"
    },
    {
      "nct_id": "NCT01305148",
      "title": "Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anti-coagulation Therapy",
        "DVT",
        "Pulmonary Embolism",
        "Joint Surgery Multiple",
        "Atrial Fibrillation",
        "Prosthetic Replacement of Mitral Valve"
      ],
      "interventions": [
        {
          "name": "Warfarin GenoSTAT Test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Iverson Genetic Diagnostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 3800,
      "start_date": "2011-08",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2015-08-31",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01305148"
    },
    {
      "nct_id": "NCT03325426",
      "title": "Activity Trackers for Improving BP",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension",
        "Cardiovascular Risk Factor",
        "Physical Activity",
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "FitBit",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "8 Years to 30 Years"
      },
      "enrollment_count": 63,
      "start_date": "2017-06-01",
      "completion_date": "2021-01-01",
      "has_results": true,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-11-15T05:22:05.592Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03325426"
    }
  ]
}